Recursion Pharmaceuticals Inc (RXRX NASDAQ) stock market data APIs

$6.96 0.64(10.1%)
as of January 14, 2025

Recursion Pharmaceuticals Inc Financial Data Overview

Price chart is built with Anychart

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Prev. Close 6.32
Open 6.96
Volume 18 259 K
High 6.96
Low 6.2
52 wk Range 5.6-15.74
Market Cap 2 469 M
Shares Outstanding 384 M
Revenue 65 184 K
EPS -0.34
Beta 0.802

Why to choose EODHD?

Prices start at $19.99

24/7 Live support

Robust, powerful and reliable data

API Simplicity of a few lines of code


Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW

Get Recursion Pharmaceuticals Inc data using free add-ons & libraries


Get Recursion Pharmaceuticals Inc Fundamental Data

Recursion Pharmaceuticals Inc Fundamental data includes:

  • Net Revenue: 65 184 K
  • EBITDA: -364 150 016
  • Earnings Per Share: -1
  • Income Statements
  • Balance Sheets
  • Cash flows

Plans with Fundamental data

Starting from

$ 59.99 /mo.
COMPARE PLANS

End-of-day & Earnings data

Get Recursion Pharmaceuticals Inc Earnings data

Calendar & News package for

$ 19.99 /mo.

What’s included:

  • Latest Release: 2024-11-06
  • EPS/Forecast: -0.35
GET THE PACKAGE

Get Recursion Pharmaceuticals Inc End-of-day data

EOD Historical Data package for

$ 19.99 /mo.

What’s included:

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
GET THE PACKAGE

Recursion Pharmaceuticals Inc News

Get Apple Inc fresh news feed via Financial News API

Calendar & News package for

$19.99/mo.

Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW
  • Flexibility: No long-term commitments, just a minimum of one month
  • Instant access: Get your API key and instructions within seconds of subscribing
  • Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.

What’s included:

  • API Calls per Day: 100 000/day
  • API Requests per Min.: 1000/minute
  • Type of Usage: Personal use

Data access:

Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.

GET THE PACKAGE
Chat